Trial reportRevista espanola de cardiologia (English ed.)2022
Plasma acylcarnitines and risk of incident heart failure and atrial fibrillation: the Prevención con dieta mediterránea study.
Trial report in Revista espanola de cardiologia (English ed.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 12 citations in OpenAlex.
- A multi-metabolite signature robustly predicts long-term mortality in the PREDIMED trial and several US cohorts.Metabolism: clinical and experimental · 2025Trial
- A machine learning approach to conglomerate multi-domain features of cardiac aging.European heart journal. Digital health · 2026Article
- Plasma metabolites in patients of the REDINSCOR III registry hospitalised for de novo heart failure with preserved ejection fraction: Prognostic implications of linoleamide and 2-trans,4-cisdecadienoylcarnitine levels.Clinical and translational medicine · 2025Article
- Prospective association between plasma amino acids and healthy aging in older adults.Journal of internal medicine · 2025Article
- The source of dietary fat influences anti-tumour immunity in obese mice.Nature metabolism · 2025Article
- Integrating metabolomics and proteomics to identify novel drug targets for heart failure and atrial fibrillation.Genome medicine · 2024Article
- Olive oil consumption, plasma metabolites, and risk of type 2 diabetes and cardiovascular disease.Cardiovascular diabetology · 2023Article
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 8 institutions in 3 countries.
Funding
Abstract
INTRODUCTION AND
objectivesFatty acid metabolic dysregulation in mitochondria is a common mechanism involved in the development of heart failure (HF) and atrial fibrillation (AF). We evaluated the association between plasma acylcarnitine levels and the incidence of HF or AF, and whether the mediterranean diet (MedDiet) may attenuate the association between acylcarnitines and HF or AF risk.
methodsTwo case-control studies nested within the Prevención con dieta mediterránea (PREDIMED) trial. High cardiovascular risk participants were recruited in Spain: 326 incident HF and 509 AF cases individually matched to 1 to 3 controls. Plasma acylcarnitines were measured with high-throughput liquid chromatography-tandem mass spectrometry. Conditional logistic regression models were fitted to estimate multivariable OR and 95%CI. Additive and multiplicative interactions were assessed by intervention group, obesity (body mass index ≥ 30 kg/m
resultsElevated levels of medium- and long-chain acylcarnitines were associated with increased HF risk (adjusted OR
conclusionsAmong individuals at high cardiovascular risk, elevated long-chain acylcarnitines were associated with a higher risk of incident HF and AF. An intervention with MedDiet+extra-virgin olive oil may reduce AF risk associated with long-chain acylcarnitines. This trial was registered at controlled-trials.com (Identifier: ISRCTN35739639).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.